DE3024623C2 - - Google Patents
Info
- Publication number
- DE3024623C2 DE3024623C2 DE3024623A DE3024623A DE3024623C2 DE 3024623 C2 DE3024623 C2 DE 3024623C2 DE 3024623 A DE3024623 A DE 3024623A DE 3024623 A DE3024623 A DE 3024623A DE 3024623 C2 DE3024623 C2 DE 3024623C2
- Authority
- DE
- Germany
- Prior art keywords
- colostrum
- use according
- solution
- tear fluid
- skimmed
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired
Links
- 210000003022 colostrum Anatomy 0.000 claims description 30
- 235000021277 colostrum Nutrition 0.000 claims description 30
- 239000000243 solution Substances 0.000 claims description 14
- 108010063045 Lactoferrin Proteins 0.000 claims description 6
- 102000012174 Lactotransferrin Human genes 0.000 claims description 6
- 238000010790 dilution Methods 0.000 claims description 5
- 239000012895 dilution Substances 0.000 claims description 5
- 239000002674 ointment Substances 0.000 claims description 5
- 239000004480 active ingredient Substances 0.000 claims description 4
- 210000002966 serum Anatomy 0.000 claims description 4
- 239000003755 preservative agent Substances 0.000 claims description 2
- 230000002335 preservative effect Effects 0.000 claims description 2
- 102000002070 Transferrins Human genes 0.000 claims 1
- 108010015865 Transferrins Proteins 0.000 claims 1
- 239000012224 working solution Substances 0.000 claims 1
- 239000012530 fluid Substances 0.000 description 12
- 239000000203 mixture Substances 0.000 description 8
- 239000003795 chemical substances by application Substances 0.000 description 5
- 102000004169 proteins and genes Human genes 0.000 description 5
- 108090000623 proteins and genes Proteins 0.000 description 5
- XEEYBQQBJWHFJM-UHFFFAOYSA-N Iron Chemical compound [Fe] XEEYBQQBJWHFJM-UHFFFAOYSA-N 0.000 description 4
- 230000005764 inhibitory process Effects 0.000 description 4
- 235000018102 proteins Nutrition 0.000 description 4
- 102000016943 Muramidase Human genes 0.000 description 3
- 108010014251 Muramidase Proteins 0.000 description 3
- 108010062010 N-Acetylmuramoyl-L-alanine Amidase Proteins 0.000 description 3
- 230000003385 bacteriostatic effect Effects 0.000 description 3
- 235000010335 lysozyme Nutrition 0.000 description 3
- 239000004325 lysozyme Substances 0.000 description 3
- 229960000274 lysozyme Drugs 0.000 description 3
- 208000011580 syndromic disease Diseases 0.000 description 3
- YBJHBAHKTGYVGT-ZKWXMUAHSA-N (+)-Biotin Chemical compound N1C(=O)N[C@@H]2[C@H](CCCCC(=O)O)SC[C@@H]21 YBJHBAHKTGYVGT-ZKWXMUAHSA-N 0.000 description 2
- GHOKWGTUZJEAQD-ZETCQYMHSA-N (D)-(+)-Pantothenic acid Chemical compound OCC(C)(C)[C@@H](O)C(=O)NCCC(O)=O GHOKWGTUZJEAQD-ZETCQYMHSA-N 0.000 description 2
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 2
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 2
- CDBYLPFSWZWCQE-UHFFFAOYSA-L Sodium Carbonate Chemical compound [Na+].[Na+].[O-]C([O-])=O CDBYLPFSWZWCQE-UHFFFAOYSA-L 0.000 description 2
- 230000003110 anti-inflammatory effect Effects 0.000 description 2
- 229910021538 borax Inorganic materials 0.000 description 2
- KGBXLFKZBHKPEV-UHFFFAOYSA-N boric acid Chemical compound OB(O)O KGBXLFKZBHKPEV-UHFFFAOYSA-N 0.000 description 2
- 239000004327 boric acid Substances 0.000 description 2
- 229960002424 collagenase Drugs 0.000 description 2
- 239000006071 cream Substances 0.000 description 2
- 235000013365 dairy product Nutrition 0.000 description 2
- 230000000694 effects Effects 0.000 description 2
- OVBPIULPVIDEAO-LBPRGKRZSA-N folic acid Chemical compound C=1N=C2NC(N)=NC(=O)C2=NC=1CNC1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 OVBPIULPVIDEAO-LBPRGKRZSA-N 0.000 description 2
- 229910052742 iron Inorganic materials 0.000 description 2
- 239000007788 liquid Substances 0.000 description 2
- 229920000609 methyl cellulose Polymers 0.000 description 2
- 239000001923 methylcellulose Substances 0.000 description 2
- 235000010981 methylcellulose Nutrition 0.000 description 2
- 235000013336 milk Nutrition 0.000 description 2
- 239000008267 milk Substances 0.000 description 2
- 210000004080 milk Anatomy 0.000 description 2
- 235000015097 nutrients Nutrition 0.000 description 2
- 238000002360 preparation method Methods 0.000 description 2
- 239000000047 product Substances 0.000 description 2
- 230000001737 promoting effect Effects 0.000 description 2
- 125000001436 propyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])[H] 0.000 description 2
- 239000011734 sodium Substances 0.000 description 2
- 229910052708 sodium Inorganic materials 0.000 description 2
- 235000010339 sodium tetraborate Nutrition 0.000 description 2
- 238000006467 substitution reaction Methods 0.000 description 2
- RTKIYNMVFMVABJ-UHFFFAOYSA-L thimerosal Chemical compound [Na+].CC[Hg]SC1=CC=CC=C1C([O-])=O RTKIYNMVFMVABJ-UHFFFAOYSA-L 0.000 description 2
- BSVBQGMMJUBVOD-UHFFFAOYSA-N trisodium borate Chemical compound [Na+].[Na+].[Na+].[O-]B([O-])[O-] BSVBQGMMJUBVOD-UHFFFAOYSA-N 0.000 description 2
- 230000029663 wound healing Effects 0.000 description 2
- 208000002874 Acne Vulgaris Diseases 0.000 description 1
- 102000009027 Albumins Human genes 0.000 description 1
- 108010088751 Albumins Proteins 0.000 description 1
- 102000004506 Blood Proteins Human genes 0.000 description 1
- 108010017384 Blood Proteins Proteins 0.000 description 1
- 241000283690 Bos taurus Species 0.000 description 1
- 102000011632 Caseins Human genes 0.000 description 1
- 108010076119 Caseins Proteins 0.000 description 1
- GHOKWGTUZJEAQD-UHFFFAOYSA-N Chick antidermatitis factor Natural products OCC(C)(C)C(O)C(=O)NCCC(O)=O GHOKWGTUZJEAQD-UHFFFAOYSA-N 0.000 description 1
- SHWNNYZBHZIQQV-UHFFFAOYSA-J EDTA monocalcium diisodium salt Chemical compound [Na+].[Na+].[Ca+2].[O-]C(=O)CN(CC([O-])=O)CCN(CC([O-])=O)CC([O-])=O SHWNNYZBHZIQQV-UHFFFAOYSA-J 0.000 description 1
- 241000792859 Enema Species 0.000 description 1
- 241000588724 Escherichia coli Species 0.000 description 1
- 206010061166 Gastroenteritis bacterial Diseases 0.000 description 1
- 102000006395 Globulins Human genes 0.000 description 1
- 108010044091 Globulins Proteins 0.000 description 1
- 108060003951 Immunoglobulin Proteins 0.000 description 1
- 102000008192 Lactoglobulins Human genes 0.000 description 1
- 108010060630 Lactoglobulins Proteins 0.000 description 1
- 241000124008 Mammalia Species 0.000 description 1
- 241000191938 Micrococcus luteus Species 0.000 description 1
- OVBPIULPVIDEAO-UHFFFAOYSA-N N-Pteroyl-L-glutaminsaeure Natural products C=1N=C2NC(N)=NC(=O)C2=NC=1CNC1=CC=C(C(=O)NC(CCC(O)=O)C(O)=O)C=C1 OVBPIULPVIDEAO-UHFFFAOYSA-N 0.000 description 1
- PVNIIMVLHYAWGP-UHFFFAOYSA-N Niacin Chemical compound OC(=O)C1=CC=CN=C1 PVNIIMVLHYAWGP-UHFFFAOYSA-N 0.000 description 1
- 102000007562 Serum Albumin Human genes 0.000 description 1
- 108010071390 Serum Albumin Proteins 0.000 description 1
- 206010064996 Ulcerative keratitis Diseases 0.000 description 1
- 239000005862 Whey Substances 0.000 description 1
- 102000007544 Whey Proteins Human genes 0.000 description 1
- 108010046377 Whey Proteins Proteins 0.000 description 1
- 206010000496 acne Diseases 0.000 description 1
- 102000015395 alpha 1-Antitrypsin Human genes 0.000 description 1
- 108010050122 alpha 1-Antitrypsin Proteins 0.000 description 1
- 229940024142 alpha 1-antitrypsin Drugs 0.000 description 1
- 235000001014 amino acid Nutrition 0.000 description 1
- 150000001413 amino acids Chemical class 0.000 description 1
- 230000002421 anti-septic effect Effects 0.000 description 1
- 230000000259 anti-tumor effect Effects 0.000 description 1
- 235000008452 baby food Nutrition 0.000 description 1
- 230000001420 bacteriolytic effect Effects 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 239000011616 biotin Substances 0.000 description 1
- 229960002685 biotin Drugs 0.000 description 1
- 235000020958 biotin Nutrition 0.000 description 1
- 239000005018 casein Substances 0.000 description 1
- BECPQYXYKAMYBN-UHFFFAOYSA-N casein, tech. Chemical compound NCCCCC(C(O)=O)N=C(O)C(CC(O)=O)N=C(O)C(CCC(O)=N)N=C(O)C(CC(C)C)N=C(O)C(CCC(O)=O)N=C(O)C(CC(O)=O)N=C(O)C(CCC(O)=O)N=C(O)C(C(C)O)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=O)N=C(O)C(CCC(O)=O)N=C(O)C(COP(O)(O)=O)N=C(O)C(CCC(O)=N)N=C(O)C(N)CC1=CC=CC=C1 BECPQYXYKAMYBN-UHFFFAOYSA-N 0.000 description 1
- 235000021240 caseins Nutrition 0.000 description 1
- 229960003333 chlorhexidine gluconate Drugs 0.000 description 1
- YZIYKJHYYHPJIB-UUPCJSQJSA-N chlorhexidine gluconate Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C(O)=O.OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C(O)=O.C1=CC(Cl)=CC=C1NC(=N)NC(=N)NCCCCCCNC(=N)NC(=N)NC1=CC=C(Cl)C=C1 YZIYKJHYYHPJIB-UUPCJSQJSA-N 0.000 description 1
- 239000012141 concentrate Substances 0.000 description 1
- 201000007717 corneal ulcer Diseases 0.000 description 1
- 235000005911 diet Nutrition 0.000 description 1
- 230000000378 dietary effect Effects 0.000 description 1
- 239000003085 diluting agent Substances 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 239000007920 enema Substances 0.000 description 1
- 229940095399 enema Drugs 0.000 description 1
- 235000019441 ethanol Nutrition 0.000 description 1
- 239000004744 fabric Substances 0.000 description 1
- 235000013861 fat-free Nutrition 0.000 description 1
- 229960000304 folic acid Drugs 0.000 description 1
- 235000019152 folic acid Nutrition 0.000 description 1
- 239000011724 folic acid Substances 0.000 description 1
- 230000000521 hyperimmunizing effect Effects 0.000 description 1
- 102000018358 immunoglobulin Human genes 0.000 description 1
- 229940099472 immunoglobulin a Drugs 0.000 description 1
- 229940072221 immunoglobulins Drugs 0.000 description 1
- 239000003112 inhibitor Substances 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 238000007689 inspection Methods 0.000 description 1
- 230000005865 ionizing radiation Effects 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 230000004060 metabolic process Effects 0.000 description 1
- 238000000034 method Methods 0.000 description 1
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 1
- 235000010270 methyl p-hydroxybenzoate Nutrition 0.000 description 1
- 239000004292 methyl p-hydroxybenzoate Substances 0.000 description 1
- LXCFILQKKLGQFO-UHFFFAOYSA-N methylparaben Chemical compound COC(=O)C1=CC=C(O)C=C1 LXCFILQKKLGQFO-UHFFFAOYSA-N 0.000 description 1
- 244000005700 microbiome Species 0.000 description 1
- 210000004400 mucous membrane Anatomy 0.000 description 1
- 229930014626 natural product Natural products 0.000 description 1
- 230000007935 neutral effect Effects 0.000 description 1
- 235000016709 nutrition Nutrition 0.000 description 1
- 229940055726 pantothenic acid Drugs 0.000 description 1
- 235000019161 pantothenic acid Nutrition 0.000 description 1
- 239000011713 pantothenic acid Substances 0.000 description 1
- 239000003961 penetration enhancing agent Substances 0.000 description 1
- 239000002504 physiological saline solution Substances 0.000 description 1
- 239000002244 precipitate Substances 0.000 description 1
- 238000001556 precipitation Methods 0.000 description 1
- 235000010232 propyl p-hydroxybenzoate Nutrition 0.000 description 1
- 239000004405 propyl p-hydroxybenzoate Substances 0.000 description 1
- 229940070376 protein Drugs 0.000 description 1
- 230000037390 scarring Effects 0.000 description 1
- 210000002374 sebum Anatomy 0.000 description 1
- 230000035807 sensation Effects 0.000 description 1
- 238000000926 separation method Methods 0.000 description 1
- 229910000029 sodium carbonate Inorganic materials 0.000 description 1
- 230000000087 stabilizing effect Effects 0.000 description 1
- 230000001954 sterilising effect Effects 0.000 description 1
- 238000004659 sterilization and disinfection Methods 0.000 description 1
- 235000000346 sugar Nutrition 0.000 description 1
- 150000008163 sugars Chemical class 0.000 description 1
- 229940124597 therapeutic agent Drugs 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- 230000001256 tonic effect Effects 0.000 description 1
- 238000000108 ultra-filtration Methods 0.000 description 1
- 235000013343 vitamin Nutrition 0.000 description 1
- 239000011782 vitamin Substances 0.000 description 1
- 229930003231 vitamin Natural products 0.000 description 1
- 229940088594 vitamin Drugs 0.000 description 1
- 235000019155 vitamin A Nutrition 0.000 description 1
- 239000011719 vitamin A Substances 0.000 description 1
- 235000010374 vitamin B1 Nutrition 0.000 description 1
- 239000011691 vitamin B1 Substances 0.000 description 1
- 235000019166 vitamin D Nutrition 0.000 description 1
- 239000011710 vitamin D Substances 0.000 description 1
- 235000019165 vitamin E Nutrition 0.000 description 1
- 239000011709 vitamin E Substances 0.000 description 1
- 239000002699 waste material Substances 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
- 230000036642 wellbeing Effects 0.000 description 1
- 239000003357 wound healing promoting agent Substances 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/96—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution
- A61K8/98—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution of animal origin
- A61K8/981—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution of animal origin of mammals or bird
- A61K8/986—Milk; Derivatives thereof, e.g. butter
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
- A61K35/20—Milk; Whey; Colostrum
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q19/00—Preparations for care of the skin
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Zoology (AREA)
- Pharmacology & Pharmacy (AREA)
- Engineering & Computer Science (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Immunology (AREA)
- Birds (AREA)
- Developmental Biology & Embryology (AREA)
- Cell Biology (AREA)
- Biotechnology (AREA)
- Biomedical Technology (AREA)
- Dermatology (AREA)
- Virology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Ophthalmology & Optometry (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Medicinal Preparation (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| FR7917118A FR2460135A1 (fr) | 1979-07-02 | 1979-07-02 | Composition a usage externe a base de colostrum |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| DE3024623A1 DE3024623A1 (de) | 1981-01-22 |
| DE3024623C2 true DE3024623C2 (https=) | 1989-10-26 |
Family
ID=9227385
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| DE19803024623 Granted DE3024623A1 (de) | 1979-07-02 | 1980-06-30 | Mittel fuer aeusserliche anwendung auf der grundlage von kolostrum |
Country Status (10)
| Country | Link |
|---|---|
| US (1) | US4342747A (https=) |
| JP (1) | JPS5653612A (https=) |
| BE (1) | BE883935A (https=) |
| CH (1) | CH644269A5 (https=) |
| DE (1) | DE3024623A1 (https=) |
| FR (1) | FR2460135A1 (https=) |
| GB (1) | GB2052979B (https=) |
| IT (1) | IT1130487B (https=) |
| MA (1) | MA18877A1 (https=) |
| NL (1) | NL8003802A (https=) |
Families Citing this family (20)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU4549985A (en) * | 1984-07-13 | 1986-02-10 | Economix Kozgazdasz Egyetemi Kisszovetkezet | Process for the preparation of a pharmaceutical composition influencing the tissue metabolism and having a regenerating action |
| FR2627386A1 (fr) * | 1988-02-22 | 1989-08-25 | Serge Liotet | Composition a usage externe destinee a l'administration oculaire |
| FR2628973B1 (fr) * | 1988-03-25 | 1990-11-16 | Gattefosse Ets Sa | Composition cosmetique ou pharmaceutique a usage cutane, et procede pour la preparation d'une telle composition |
| DE3924420A1 (de) * | 1989-07-24 | 1991-01-31 | Biotest Pharma Gmbh | Verfahren zur herstellung eines immunglobulin-praeparates aus kolostrum |
| DE4026365A1 (de) | 1990-08-21 | 1992-02-27 | Biotest Pharma Gmbh | Sterilfiltrierte kolostralmilch |
| ATE148631T1 (de) * | 1990-11-13 | 1997-02-15 | Santen Pharmaceutical Co Ltd | Therapeutische agens bei hornhautverletzungen |
| FR2676331B1 (fr) * | 1991-05-17 | 1993-09-03 | Opsia Pharma | Milieu de conservation d'organes, de tissus ou de cellules. |
| DE69309712T2 (de) * | 1993-01-26 | 1997-10-23 | Horse Vitality Ltd | Pharmazeutische und dermokosmetische mittel enthaltend pferdecolostrum |
| AU6847894A (en) * | 1993-06-23 | 1995-01-17 | Viable Bioproducts Ltd. | Method for the improvement of wound healing and compositions therefor |
| ATE227557T1 (de) * | 1995-04-28 | 2002-11-15 | Sara Lee De Nv | Verwendung von zahnpflegemitteln enthaltend bovines kolostrum |
| JP3118584B2 (ja) * | 1995-05-08 | 2000-12-18 | 参天製薬株式会社 | 術後乱視予防剤 |
| DE19537297A1 (de) * | 1995-07-07 | 1997-01-09 | Paerson & Co Gmbh & Co | Kosmetische Präparate mit Wachstumsfaktoren hergestellt aus Milch und Kolostrum von Kühen und Stuten |
| AUPN642795A0 (en) * | 1995-11-08 | 1995-11-30 | Northfield Laboratories Pty Ltd | Dairy compositions and methods of preparing same |
| US20030203839A1 (en) * | 1999-10-29 | 2003-10-30 | Kruzel Marian L. | Immune enhancing composition containing lactoferrin |
| US20060013889A1 (en) * | 2004-07-16 | 2006-01-19 | Playford Raymond J | Colostrum-based treatment for irritable bowel syndrome |
| US7426440B2 (en) * | 2004-09-24 | 2008-09-16 | Nutritional Bioscience Ltd. | Repair and protection factor scoring method for bioactive agents |
| US20060068022A1 (en) * | 2004-09-29 | 2006-03-30 | Playford Raymond J | Bioactive agent compositions for repair of cell injuries |
| BRPI0721321A2 (pt) * | 2007-02-20 | 2013-01-08 | Nutricia Nv | uso de colostro, e, composiÇço |
| DK2797609T3 (en) * | 2011-12-30 | 2017-01-09 | Innomed S A | COMBINING growth factors, cytokines, anti-bacterial / ANTIVIRALS FACTORS STEM CELL-STIMULATING FACTORS, complement C3A / C4A, immunoglobulins, and chemotactic factors |
| ITMI20112440A1 (it) * | 2011-12-30 | 2013-07-01 | Bionest Ltd | Formulazioni contenenti citochine, fattori di crescita, chemiotattici, antibatterici ed eventualmente immunoglobuline e complemento, per la terapia topica delle lesioni corneali |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB467825A (en) * | 1935-12-23 | 1937-06-23 | Gyula Groh | Process for the production of substances for promoting the growth of backward infants |
| GB734117A (en) * | 1952-04-28 | 1955-07-27 | Evagoras Joannou Georgiou | Preparation of a substance for the treatment of malignant tumours |
| FR2360313A1 (fr) * | 1976-08-03 | 1978-03-03 | Fabre Sa Pierre | Compositions pharmaceutiques utiles notamment pour le traitement de la seborrhee |
| CH627079A5 (en) * | 1977-04-15 | 1981-12-31 | Nestle Sa | Process for preparing a protein concentrate containing immunological factors of milk origin |
-
1979
- 1979-07-02 FR FR7917118A patent/FR2460135A1/fr active Granted
-
1980
- 1980-06-19 MA MA19075A patent/MA18877A1/fr unknown
- 1980-06-20 BE BE0/201117A patent/BE883935A/fr not_active IP Right Cessation
- 1980-06-23 GB GB8020439A patent/GB2052979B/en not_active Expired
- 1980-06-26 US US06/163,189 patent/US4342747A/en not_active Expired - Lifetime
- 1980-06-30 DE DE19803024623 patent/DE3024623A1/de active Granted
- 1980-07-01 IT IT68031/80A patent/IT1130487B/it active
- 1980-07-01 CH CH505380A patent/CH644269A5/fr not_active IP Right Cessation
- 1980-07-01 NL NL8003802A patent/NL8003802A/nl not_active Application Discontinuation
- 1980-07-01 JP JP8988780A patent/JPS5653612A/ja active Granted
Also Published As
| Publication number | Publication date |
|---|---|
| FR2460135B1 (https=) | 1982-11-19 |
| JPH021127B2 (https=) | 1990-01-10 |
| IT1130487B (it) | 1986-06-11 |
| JPS5653612A (en) | 1981-05-13 |
| IT8068031A0 (it) | 1980-07-01 |
| NL8003802A (nl) | 1981-01-06 |
| DE3024623A1 (de) | 1981-01-22 |
| GB2052979A (en) | 1981-02-04 |
| MA18877A1 (fr) | 1980-12-31 |
| US4342747A (en) | 1982-08-03 |
| FR2460135A1 (fr) | 1981-01-23 |
| BE883935A (fr) | 1980-10-16 |
| GB2052979B (en) | 1984-02-29 |
| CH644269A5 (fr) | 1984-07-31 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| DE3024623C2 (https=) | ||
| DE2813984C2 (https=) | ||
| DE69528258T2 (de) | Haiknorpelextrakte mit antiangiogenischer wirkung und einem effekt auf tumorregression und verfahren zur herstellung derselben | |
| DE3686410T2 (de) | Stabilisierte zusammensetzungen von menschlichen aktivatoren des gewebeplasminogens. | |
| DE69115909T2 (de) | Verwendung von Phospholipiden zur Herstellung eines topischen Arzneimittels zur Beinflussung des Serumcholesterinspiegels | |
| DE69133442T2 (de) | Wachstumsfördernder wirkstoff | |
| DE69535593T2 (de) | Verwendung von hgf zur herstellung eines arzneimittels zur behandlung von lungenfibrose | |
| DE69431300T2 (de) | Eine pharmazeutische oder kosmetische zubereitung, die eine kolostrumfraktion enthält und deren medizinische verwendung | |
| DE69021415T2 (de) | Mittel zur Behandlung von seniler Demenz, Gedächtnisstörungen und ähnlichen Zuständen. | |
| DE60124591T2 (de) | Agastache rugosa extrakt mit entzündungshemmender wirkung und antiatherogener wirkung | |
| DE4337654C2 (de) | Verwendung boviner Kolostralmilch von nicht mit Viren hyperimmunisierten Tieren als Leberschutzpräparat | |
| EP0918464B1 (de) | Verfahren zur herstellung von kolostralmilchprodukten sowie deren verwendung | |
| DE69727583T2 (de) | Vermeidung von gastrointestinaler schädigung | |
| DE2605576C3 (de) | Verfahren zum Isolieren der Proteasen Papain,,Chimopapain, Lysozym und Proteinase X aus dem Milchsaft von Carica papya und Verwendung der isolierten Proteasen zur Herstellung von sterilisierten und Iyophilisirten orthopädischen, neurochirurgischen oder ophthalmologischen Präparaten | |
| DE1076888B (de) | Verfahren zur Gewinnung atmungsfoerdernder Wirkstoffe fuer therapeutische Zwecke | |
| DE69522723T2 (de) | Antiallergisches Mittel und Nährstoffzusammensetzung, die Glutamin enthalten | |
| WO1998006409A2 (de) | Vitamin a-haltige zusammensetzung und deren verwendung insbesondere gegen hauterkrankungen | |
| DE69534016T2 (de) | Verwendung von thrombomodulin gegen lebererkrankungen | |
| DE69929189T2 (de) | Ein Komplex aus Alpha-Fetoprotein (AFP) und einem polyungesättigten Fettsäurederivat zur Behandlung von Immunschwäche | |
| DE2037942A1 (de) | Arzneimittel zur Verhinderung der Atheroklerose und des Wiederauftretens kardiocaskulärer Anfälle bei atherosklerotischen Säugetieren | |
| DE69519848T2 (de) | Verfahren zum Herstellen eines Arzneimittels | |
| DE69417872T2 (de) | Inhibitor peptid spezifisch für cathepsin-l | |
| WO2004071524A1 (de) | Albuminlösung und verfahren zu ihrer herstellung | |
| DE69113437T2 (de) | Therapeutische Mittel für diabetisches Gangrän. | |
| DE69729721T2 (de) | Heilmittel für keratokonjunktivitis |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| 8110 | Request for examination paragraph 44 | ||
| D2 | Grant after examination | ||
| 8380 | Miscellaneous part iii |
Free format text: AUF DER TITELSEITE DER PATENTSCHRIFT IST DIE ZEICHNUNG FIG.1 ZU STREICHEN |
|
| 8364 | No opposition during term of opposition | ||
| 8339 | Ceased/non-payment of the annual fee |